Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Oxidative stress and neopterin abnormalities in schizophrenia: a longitudinal study.

Chittiprol S, Venkatasubramanian G, Neelakantachar N, Babu SV, Reddy NA, Shetty KT, Gangadhar BN.

J Psychiatr Res. 2010 Apr;44(5):310-3. doi: 10.1016/j.jpsychires.2009.09.002.

PMID:
19850302
2.

Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment.

Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1164-9.

PMID:
17459548
3.

Longitudinal study of beta2-microglobulin abnormalities in schizophrenia.

Chittiprol S, Venkatasubramanian G, Neelakantachar N, Reddy NA, Shetty KT, Gangadhar BN.

Int Immunopharmacol. 2009 Sep;9(10):1215-7. doi: 10.1016/j.intimp.2009.07.002.

PMID:
19596084
4.

A defect in the antioxidant defense system in schizophrenia.

Virit O, Altindag A, Yumru M, Dalkilic A, Savas HA, Selek S, Erel O, Herken H.

Neuropsychobiology. 2009;60(2):87-93. doi: 10.1159/000239684.

PMID:
19776652
5.

Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia.

Dakhale GN, Khanzode SD, Khanzode SS, Saoji A.

Psychopharmacology (Berl). 2005 Nov;182(4):494-8.

PMID:
16133138
6.

Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.

Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A.

Neuropsychobiology. 2004;49(4):205-9.

PMID:
15154399
7.

The changes of aggregability of blood platelets in schizophrenia.

Dietrich-Muszalska A, Olas B.

World J Biol Psychiatry. 2009;10(2):171-6.

PMID:
19514099
8.

Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients.

Mackeprang T, Kristiansen KT, Glenthoj BY.

Biol Psychiatry. 2002 Nov 1;52(9):863-73.

PMID:
12399139
9.

The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance.

Akyol O, Herken H, Uz E, Fadillioğlu E, Unal S, Söğüt S, Ozyurt H, Savaş HA.

Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jun;26(5):995-1005.

PMID:
12369276
10.

Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment.

Pirildar S, Gönül AS, Taneli F, Akdeniz F.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jul;28(4):709-13.

PMID:
15276697
11.

[Peripheral blood T-lymphocyte and T-lymphocyte subset ratios before and after treatment in schizophrenia patients not taking antipsychotic medication].

Baskak SC, Ozsan H, Baskak B, Devrimci Ozgüven H, Kinikli G.

Turk Psikiyatri Derg. 2008 Spring;19(1):5-12. Turkish.

12.

Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.

Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M, Jasovic-Gasic M, Dieguez C, Casanueva FF.

Neuroendocrinology. 2007;85(4):249-56.

PMID:
17570902
13.

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients.

Ascher-Svanum H, Peng X, Faries D, Montgomery W, Haddad PM.

BMC Psychiatry. 2009 Jul 29;9:46. doi: 10.1186/1471-244X-9-46.

14.

Abnormal age-related changes of plasma antioxidant proteins in schizophrenia.

Yao JK, Reddy R, van Kammen DP.

Psychiatry Res. 2000 Dec 27;97(2-3):137-51.

PMID:
11166086
15.

Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment.

Ling SH, Tang YL, Jiang F, Wiste A, Guo SS, Weng YZ, Yang TS.

J Psychiatr Res. 2007 Jan-Feb;41(1-2):36-42.

PMID:
16403530
16.

Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients.

Miljevic C, Nikolic M, Nikolic-Kokic A, Jones DR, Niketic V, Lecic-Tosevski D, Spasic MB.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Mar 17;34(2):303-7. doi: 10.1016/j.pnpbp.2009.11.024.

PMID:
19962416
17.

Beta2-microglobulin abnormalities in antipsychotic-naïve schizophrenia: evidence for immune pathogenesis.

Chittiprol S, Venkatasubramanian G, Neelakantachar N, Allha N, Shetty KT, Gangadhar BN.

Brain Behav Immun. 2009 Feb;23(2):189-92. doi: 10.1016/j.bbi.2008.08.007.

PMID:
18801425
18.

The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.

Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandöl E.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1493-9.

PMID:
17688987
19.
20.

D-serine serum levels in patients with schizophrenia: relation to psychopathology and comparison to healthy subjects.

Hons J, Zirko R, Ulrychova M, Cermakova E, Libiger J.

Neuro Endocrinol Lett. 2008 Aug;29(4):485-92.

PMID:
18766161
Items per page

Supplemental Content

Support Center